Alnylam Pharmaceuticals
Director, Clinical Research (Finance)
Alnylam is the industry leader in the translation of RNA interference (RNAi) into a new class of innovative medicines with the potential to address the unmet needs of patients with debilitating diseases. Founded in 2002, Alnylam was built upon a bold vision of turning scientific possibility into reality, and is now advancing a robust pipeline of investigational RNAi therapeutic medicines, including five programs in late-stage development. In 2018, Alnylam received approval for our first product, the first-ever RNAi therapeutic, by the FDA in the U.S. for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults and by the European Medicines Agency in the EU for the treatment of hATTR amyloidosis in adults with stage 1 or stage 2 polyneuropathy. Headquartered in Cambridge, Mass., Alnylam employs over 1,200 people in 18 countries and is rapidly growing globally, with additional offices in Norton, Mass., Maidenhead, U.K., Zug, Switzerland, Amsterdam, Netherlands, and Tokyo, Japan. Alnylam is proud to have been recognized as one of The Boston Globe's Top Places to Work four years in a row (2015-2018) and a Great Place to Work in the U.K. and Switzerland in 2019. Please visit www.alnylam.com for more information.
Alnylam Pharmaceuticals is seeking an imaginative physician drug developer, with the flexibility and confidence to work in therapeutic areas that may be beyond their particular expertise or experience. This is an opportunity to provide clinical leadership in developing RNAi therapeutics in Alnylam's rapidly expanding portfolio, which spans the areas of rare genetic diseases, cardio-metabolic diseases and hepatic infectious diseases.
The successful candidate's primary role will be as clinical lead and Chair of Clinical Development Strategy Team for one or multiple clinical development programs across potential indications including non-alcoholic steatohepatitis (NASH). He/she is expected to play a leading and influencing role in developing overall clinical development strategies for the molecule(s) with the NASH program's alliance partner, Regeneron Pharmaceuticals, and drive progress and operational excellence for associated clinical trials through proof-of-concept. In addition, this role will lead Alnylam's clinical partnership in chronic hepatitis B research with Vir Pharmaceuticals, an alliance partner in this arena. These roles will also include interaction with Alnylam's research group, helping to advise the team on the clinical development feasibility of novel targets and the design of proof-of-concept studies. This work will also involve extensive consultation and collaboration with external experts.
The Director/Sr. Director, Clinical Development will work in a matrix organization across Preclinical, Regulatory & QA teams to ensure fully harmonized and integrated development strategies. He/she will be a key Alnylam Development spokesperson at external meetings, including regulatory interactions and scientific meetings.
Summary of Key Responsibilities
A highly driven, dynamic, engaged and accomplished physician-scientist with experience and insight will thrive in this role. Specific qualifications include:
Alnylam Pharmaceuticals is an EEO employer committed to an exciting, diverse, and enriching work environment.